BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 27988383)

  • 21. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
    Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
    United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.
    Wani S; Holmberg D; Santoni G; Kauppila JH; Farkkila M; von Euler-Chelpin M; Shaheen NJ; Lagergren J
    Gastroenterology; 2023 Oct; 165(4):909-919.e13. PubMed ID: 37279832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
    Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
    Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
    Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal Adenocarcinoma.
    Hamade N; Vennelaganti S; Parasa S; Vennalaganti P; Gaddam S; Spaander MCW; van Olphen SH; Thota PN; Kennedy KF; Bruno MJ; Vargo JJ; Mathur S; Cash BD; Sampliner R; Gupta N; Falk GW; Bansal A; Young PE; Lieberman DA; Sharma P
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):864-868. PubMed ID: 30012433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
    Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.
    Gatenby P; Bhattacharjee S; Wall C; Caygill C; Watson A
    World J Gastroenterol; 2016 Dec; 22(48):10592-10600. PubMed ID: 28082811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
    Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
    Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Barrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia.
    Picardo SL; O'Brien MP; Feighery R; O'Toole D; Ravi N; O'Farrell NJ; O'Sullivan JN; Reynolds JV
    Dis Esophagus; 2015; 28(2):121-6. PubMed ID: 24428806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.
    Sharma P; Falk GW; Weston AP; Reker D; Johnston M; Sampliner RE
    Clin Gastroenterol Hepatol; 2006 May; 4(5):566-72. PubMed ID: 16630761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
    Conio M; Blanchi S; Lapertosa G; Ferraris R; Sablich R; Marchi S; D'Onofrio V; Lacchin T; Iaquinto G; Missale G; Ravelli P; Cestari R; Benedetti G; Macrì G; Fiocca R; Munizzi F; Filiberti R
    Am J Gastroenterol; 2003 Sep; 98(9):1931-9. PubMed ID: 14499768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of lesions in dysplastic Barrett's esophagus by community and expert endoscopists.
    Schölvinck DW; van der Meulen K; Bergman JJGHM; Weusten BLAM
    Endoscopy; 2017 Feb; 49(2):113-120. PubMed ID: 27855466
    [No Abstract]   [Full Text] [Related]  

  • 35. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study.
    Thota PN; Hajifathalian K; Benjamin T; Runkana A; Lopez R; Sanaka MR
    J Dig Dis; 2017 Mar; 18(3):143-150. PubMed ID: 28188977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and Natural History of Barrett's Esophagus in Lung Transplant: A Single-Center Experience.
    Biswas Roy S; Banks P; Kunz M; Ipsen TR; Masuda T; Mittal SK; Smith MA; Bremner RM
    Ann Thorac Surg; 2019 Apr; 107(4):1017-1023. PubMed ID: 30481513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.
    Nguyen T; Thrift AP; Yu X; Duan Z; El-Serag HB
    Am J Gastroenterol; 2017 Jul; 112(7):1049-1055. PubMed ID: 28244499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
    Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
    Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium.
    Gopal DV; Lieberman DA; Magaret N; Fennerty MB; Sampliner RE; Garewal HS; Falk GW; Faigel DO
    Dig Dis Sci; 2003 Aug; 48(8):1537-41. PubMed ID: 12924649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.